189 related articles for article (PubMed ID: 22510873)
1. An activating intragenic deletion in NOTCH1 in human T-ALL.
Haydu JE; De Keersmaecker K; Duff MK; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Ferrando A
Blood; 2012 May; 119(22):5211-4. PubMed ID: 22510873
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL.
Jeannet R; Mastio J; Macias-Garcia A; Oravecz A; Ashworth T; Geimer Le Lay AS; Jost B; Le Gras S; Ghysdael J; Gridley T; Honjo T; Radtke F; Aster JC; Chan S; Kastner P
Blood; 2010 Dec; 116(25):5443-54. PubMed ID: 20829372
[TBL] [Abstract][Full Text] [Related]
3. MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.
Pajcini KV; Xu L; Shao L; Petrovic J; Palasiewicz K; Ohtani Y; Bailis W; Lee C; Wertheim GB; Mani R; Muthusamy N; Li Y; Meijerink JPP; Blacklow SC; Faryabi RB; Cherry S; Pear WS
Sci Signal; 2017 Nov; 10(505):. PubMed ID: 29138297
[TBL] [Abstract][Full Text] [Related]
4. Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1.
Ashworth TD; Pear WS; Chiang MY; Blacklow SC; Mastio J; Xu L; Kelliher M; Kastner P; Chan S; Aster JC
Blood; 2010 Dec; 116(25):5455-64. PubMed ID: 20852131
[TBL] [Abstract][Full Text] [Related]
5. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.
Dail M; Wong J; Lawrence J; O'Connor D; Nakitandwe J; Chen SC; Xu J; Lee LB; Akagi K; Li Q; Aster JC; Pear WS; Downing JR; Sampath D; Shannon K
Nature; 2014 Sep; 513(7519):512-6. PubMed ID: 25043004
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.
Palomero T; Ferrando A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3(Suppl 3):S205-10. PubMed ID: 19778842
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
Aste-Amézaga M; Zhang N; Lineberger JE; Arnold BA; Toner TJ; Gu M; Huang L; Vitelli S; Vo KT; Haytko P; Zhao JZ; Baleydier F; L'Heureux S; Wang H; Gordon WR; Thoryk E; Andrawes MB; Tiyanont K; Stegmaier K; Roti G; Ross KN; Franlin LL; Wang H; Wang F; Chastain M; Bett AJ; Audoly LP; Aster JC; Blacklow SC; Huber HE
PLoS One; 2010 Feb; 5(2):e9094. PubMed ID: 20161710
[TBL] [Abstract][Full Text] [Related]
8. Recent advances on NOTCH signaling in T-ALL.
Tzoneva G; Ferrando AA
Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of IDH1-R132H mutation in T cell acute lymphoblastic leukemia mouse model via the Notch1 pathway.
Liu Y; Fang B; Feng X; Jiang Y; Zeng Y; Jiang J
Tissue Cell; 2022 Feb; 74():101674. PubMed ID: 34814054
[TBL] [Abstract][Full Text] [Related]
10. The role of NOTCH1 signaling in T-ALL.
Ferrando AA
Hematology Am Soc Hematol Educ Program; 2009; ():353-61. PubMed ID: 20008221
[TBL] [Abstract][Full Text] [Related]
11. Murine Pten(-/-) T-ALL requires non-redundant PI3K/mTOR and DLL4/Notch1 signals for maintenance and γc/TCR signals for thymic exit.
Hagenbeek TJ; Wu X; Choy L; Sanchez-Irizarry C; Seshagiri S; Stinson J; Siebel CW; Spits H
Cancer Lett; 2014 May; 346(2):237-48. PubMed ID: 24384093
[TBL] [Abstract][Full Text] [Related]
12. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia.
Sanchez-Martin M; Ferrando A
Blood; 2017 Mar; 129(9):1124-1133. PubMed ID: 28115368
[TBL] [Abstract][Full Text] [Related]
13. Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL.
Sulis ML; Saftig P; Ferrando AA
Leukemia; 2011 Oct; 25(10):1564-9. PubMed ID: 21625236
[TBL] [Abstract][Full Text] [Related]
14. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
15. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
Silva A; Jotta PY; Silveira AB; Ribeiro D; Brandalise SR; Yunes JA; Barata JT
Haematologica; 2010 Apr; 95(4):674-8. PubMed ID: 20015880
[TBL] [Abstract][Full Text] [Related]
16. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL.
Sulis ML; Williams O; Palomero T; Tosello V; Pallikuppam S; Real PJ; Barnes K; Zuurbier L; Meijerink JP; Ferrando AA
Blood; 2008 Aug; 112(3):733-40. PubMed ID: 18411416
[TBL] [Abstract][Full Text] [Related]
17. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Larson Gedman A; Chen Q; Kugel Desmoulin S; Ge Y; LaFiura K; Haska CL; Cherian C; Devidas M; Linda SB; Taub JW; Matherly LH
Leukemia; 2009 Aug; 23(8):1417-25. PubMed ID: 19340001
[TBL] [Abstract][Full Text] [Related]
18. T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling.
Pear WS; Aster JC
Curr Opin Hematol; 2004 Nov; 11(6):426-33. PubMed ID: 15548998
[TBL] [Abstract][Full Text] [Related]
19. Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL.
Gordon WR; Roy M; Vardar-Ulu D; Garfinkel M; Mansour MR; Aster JC; Blacklow SC
Blood; 2009 Apr; 113(18):4381-90. PubMed ID: 19075186
[TBL] [Abstract][Full Text] [Related]
20. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
